Metabolic to spend $2.1m grant on clinical trials
Wednesday, 06 August, 2003
Metabolic Pharmaceuticals (ASX:MBP) has been granted an R&D Start grant of up to AUD$2.1 million to conduct its Phase IIb clinical trial for its obesity drug AOD9604.
According to CEO Chris Belyea, the grant will deliver welcome support to the trial and would leave the company in a strong financial position at the end of the trial.
It's the first grant of its kind received by the company, Belyea said. He noted that the grant would support trial expenses in Australia rather than overseas costs associated with the trial.
Metabolic's three-month trial is to be carried out in 300 patients at five Australian hospitals. Screening of patients is expected to begin in September, and the first patients will begin taking the drug in October, Belyea said.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...